vibostolimab + pembrolizumab + belzutifan

This drug is an **investigational combination therapy** composed of three agents: **vibostolimab** (an anti-TIGIT monoclonal antibody), **pembrolizumab** (a well-established anti-PD-1 monoclonal antibody), and **belzutifan** (a small molecule inhibitor of hypoxia-inducible factor 2 alpha, HIF-2α). Mechanistically, the regimen aims to enhance anti-tumor immune response through dual checkpoint inhibition (TIGIT and PD-1) synergized with targeting tumor adaptation to hypoxia (HIF-2α). This combination is primarily in clinical development, notably for advanced and metastatic solid tumors including renal cell carcinoma.